Want to join the conversation?
Drug company $PRGO reported higher 2Q16 results, helped by lower expenses in the quarter. $PRGO said net income rose 244.5% to $194.3MM, or $1.35 per share from $56.4MM, or $0.38 per share in the same quarter a year ago. Revenue fell 3.3% to $1.49Bil. Excluding items, $PRGO earned $1.93 per share, down 11% YoverY.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?